MCID: HRT012
MIFTS: 53

Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Heart Valve Disease

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 12 15 62 17 71
Valvular Heart Disease 12 15
Heart Valve Diseases 42 43
Abnormality of the Heart Valves 6
Valvular Heart Diseases 54
Heart Valve Prolapse 43

Classifications:



External Ids:

Disease Ontology 12 DOID:4079
NCIt 49 C45525
SNOMED-CT 67 368009 398995000
UMLS 71 C0018824 C0079485

Summaries for Heart Valve Disease

MedlinePlus : 42 Your heart has four valves. Normally, these valves open to let blood flow through or out of your heart, and then shut to keep it from flowing backward. But sometimes they don't work properly. If they don't, you could have Regurgitation - when blood leaks back through the valve in the wrong direction Mitral valve prolapse - when one of the valves, the mitral valve, has "floppy" flaps and doesn't close tightly. It's one of the most common heart valve conditions. Sometimes it causes regurgitation. Stenosis - when the valve doesn't open enough and blocks blood flow Valve problems can be present at birth or caused by infections, heart attacks, or heart disease or damage. The main sign of heart valve disease is an unusual heartbeat sound called a heart murmur. Your doctor can hear a heart murmur with a stethoscope. But many people have heart murmurs without having a problem. Heart tests can show if you have a heart valve disease. Some valve problems are minor and do not need treatment. Others might require medicine, medical procedures, or surgery to repair or replace the valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and sick sinus syndrome, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Heart Valve Disease is SMC1A (Structural Maintenance Of Chromosomes 1A), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and MicroRNAs in cardiomyocyte hypertrophy. The drugs Acetylcysteine and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

PubMed Health : 62 About heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves. These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Wikipedia : 74 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Related Diseases for Heart Valve Disease

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 rheumatic heart disease 33.1 TGFB1 NPPB IL1B CNMD
2 sick sinus syndrome 32.6 TGFB1 NPPA MIR423
3 dilated cardiomyopathy 32.2 TGFB1 NR3C2 NPPB NPPA MIR499A IL1B
4 cardiovascular system disease 32.2 NR3C2 NPPB NPPA MIR499A MIR423 MIR29B1
5 lipoprotein quantitative trait locus 31.5 NPPB NPPA MIR29B1 MIR21 MIR126 IL1B
6 mitral valve insufficiency 31.5 NR3C2 NPPB NPPA MIR423
7 arteries, anomalies of 31.5 MIR499A MIR423 MIR29B1 MIR21 MIR126 IL1B
8 mitral valve disease 31.3 NPPB NPPA MIR423
9 migraine with or without aura 1 31.2 IL1B HTR2B HTR2A APOH
10 heart septal defect 31.2 NPPA MIR499A MIR423
11 chronic kidney disease 31.0 TGFB1 NR3C2 NPPB NPPA IL1B
12 sleep apnea 31.0 NPPB IL1B HTR2A
13 pulmonary hypertension 31.0 NPPB NPPA MIR21 IL1B HTR2B HTR2A
14 congestive heart failure 30.9 NR3C2 NPPB NPPA IL1B
15 respiratory failure 30.9 NPPB NPPA IL1R1 IL1B
16 hypertrophic cardiomyopathy 30.9 TGFB1 NR3C2 NPPB NPPA CTF1
17 vascular disease 30.8 TGFB1 NPPB MIR21 MIR126 HTR2A APOH
18 aortic valve disease 2 30.7 NPPB NPPA MIR423 MIR29B1 MIR21 MIR126
19 diastolic heart failure 30.7 TGFB1 NPPB NPPA MIR499A
20 atrial fibrillation 30.7 TGFB1 NR3C2 NPPB NPPA MIR21 MIR126
21 aortic disease 30.6 MIR29B1 MIR21 MIR205 MIR126
22 pulmonary embolism 30.5 NPPB NPPA APOH
23 pulmonary edema 30.5 NR3C2 NPPB NPPA IL1B
24 cerebrovascular disease 30.5 NPPB NPPA MIR21 APOH
25 nervous system disease 30.5 MIR423 MIR29B1 MIR21 MIR126 IL1B
26 post-traumatic stress disorder 30.5 NR3C2 IL1B HTR2A
27 pulmonary disease, chronic obstructive 30.5 TGFB1 NPPB MIR423 MIR21 MIR126 IL1B
28 central nervous system disease 30.4 MIR423 MIR29B1 MIR21 MIR126 IL1B HTR2A
29 connective tissue disease 30.4 MIR423 MIR29B1 MIR21 MIR126 IL1B APOH
30 acute myocardial infarction 30.3 NR3C2 NPPB NPPA MIR499A MIR423 MIR21
31 heart disease 30.1 TGFB1 NR3C2 NPPB NPPA MIR499A MIR423
32 disproportionate short stature with ptosis and valvular heart lesions 11.7
33 cardiac valvular defect, developmental 11.3
34 andersen cardiodysrhythmic periodic paralysis 11.2
35 mucopolysaccharidosis, type iva 11.2
36 cardiomyopathy, familial hypertrophic, 21 11.2
37 coumarin resistance 11.1
38 cardiac valvular dysplasia, x-linked 11.1
39 tricuspid valve disease 11.1
40 cardiac tuberculosis 10.6 NR3C2 NPPB
41 vulvar vestibulitis syndrome 10.6 IL1R1 IL1B
42 apnea, obstructive sleep 10.6 NPPB IL1B HTR2A
43 idiopathic edema 10.6 NR3C2 NPPB NPPA
44 indolent myeloma 10.6 IL1R1 IL1B
45 pyoderma 10.6 IL1R1 IL1B APOH
46 hyperlipoproteinemia, type iii 10.6
47 hypoactive sexual desire disorder 10.6 HTR2B HTR2A
48 anterolateral myocardial infarction 10.6 NPPB NPPA
49 intracranial hypertension 10.6 NPPB IL1B APOH
50 pulmonary artery disease 10.6 NPPB MIR126 APOH

Graphical network of the top 20 diseases related to Heart Valve Disease:



Diseases related to Heart Valve Disease

Symptoms & Phenotypes for Heart Valve Disease

UMLS symptoms related to Heart Valve Disease:


edema, chest pain, angina pectoris, undiagnosed heart murmur

GenomeRNAi Phenotypes related to Heart Valve Disease according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.64 TGFB1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 9.64 IL1R1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.64 IL1B IL1R1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 9.64 IL1R1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.64 IL1B IL1R1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 9.64 TGFB1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-143 9.64 TGFB1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.64 NR3C2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.64 IL1B IL1R1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 9.64 NR3C2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.64 IL1B IL1R1 NR3C2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.64 IL1R1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.64 NR3C2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.64 IL1R1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 9.64 TGFB1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 9.64 NR3C2

Drugs & Therapeutics for Heart Valve Disease

PubMed Health treatment related to Heart Valve Disease: 62

Currently, no medicines can cure heart valve disease . However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve. The goals of treating heart valve disease might include: Preventing, treating, or relieving the symptoms of other related heart conditions. Protecting heart valves from further damage. Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
tannic acid Approved Phase 4 1401-55-4
4
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Etomidate Approved Phase 4 33125-97-2 36339 667484
7
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
13
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
14
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
15
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
17
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
18
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
19
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
20
Testosterone enanthate Approved Phase 4 315-37-7 9416
21
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
22
Methyltestosterone Approved Phase 4 58-18-4 6010
23
Hydralazine Approved Phase 4 86-54-4 3637
24
Ramipril Approved Phase 4 87333-19-5 5362129
25
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
26
Insulin lispro Approved Phase 4 133107-64-9
27
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
31
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
32
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
33
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
34
Morphine Approved, Investigational Phase 4 57-27-2 5288826
35
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
37
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
38
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
39
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
40
Ephedrine Approved Phase 4 299-42-3 9294
41
Pseudoephedrine Approved Phase 4 90-82-4 7028
42
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
43
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
44
Warfarin Approved Phase 4 81-81-2 6691 54678486
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
48
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
50
Simendan Investigational Phase 4 131741-08-7

Interventional clinical trials:

(show top 50) (show all 477)
# Name Status NCT ID Phase Drugs
1 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
2 The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery Unknown status NCT01623193 Phase 4
3 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
4 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
5 Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement Unknown status NCT03440268 Phase 4 N Acetyl Cysteine;Placebos
6 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
7 Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%;volume replacement
8 Sildenafil for Improving Outcomes After Valvular Correction Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
9 The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
10 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial Completed NCT01384643 Phase 4 Propofol
11 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting Completed NCT01210976 Phase 4 levosimendan;placebo
12 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
13 Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass Completed NCT02136979 Phase 4 Propofol;Sevoflurane
14 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
15 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
16 A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
17 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
18 Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery Completed NCT03280745 Phase 4 Hypertonic saline;0.9% saline
19 The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. Completed NCT01495949 Phase 4 etomidate;thiopentone
20 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial. Completed NCT01477151 Phase 4 Volatile anesthetic
21 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
22 Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC) Completed NCT00512759 Phase 4 Goal-directed preload and afterload decrement
23 Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation Completed NCT00643188 Phase 4
24 Acute Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus Completed NCT02962921 Phase 4 Insulin LISPRO intravenous loading
25 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
26 Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF) Completed NCT02827500 Phase 4 ivabradine
27 Comparison of Conscious Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Using the Transfemoral Approach: Randomized Double Blind Prospective Study Recruiting NCT03747432 Phase 4 Propofol;Dexmedetomidine
28 Effects of Remifentanil on Diastolic and Systolic Function in Patients With Diastolic Dysfunction Recruiting NCT04117009 Phase 4 Remifentanil 2 MG
29 Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University: Randomized Prospective Comparative Study Recruiting NCT04223219 Phase 4 Fentanyl;Fentanyl, Propofol;Dexmedetomidine, Ketamine, Magnesium sulfate
30 Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction - the ILO-HOPE Clinical Trial Recruiting NCT03620526 Phase 4 Iloprost;Placebo
31 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Active, not recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
32 Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial Not yet recruiting NCT04045093 Phase 4 Dabigatran etexilate;Warfarin
33 Effects of Continuous Positive Airway Pressure on Heart Remodeling in Patients With Obstructive Sleep Apnea: A Randomized Study With Cardiovascular Magnetic Resonance Imaging Terminated NCT00727454 Phase 4
34 Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial Withdrawn NCT00187304 Phase 4
35 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
36 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
37 Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial Unknown status NCT01478984 Phase 3
38 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
39 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
40 Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair Completed NCT02084069 Phase 3 Atorvastatin
41 Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial Completed NCT02833948 Phase 3 Acetylsalicylic acid;Clopidogrel;Rivaroxaban
42 Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery Completed NCT02237495 Phase 2, Phase 3 dexmedetomidine;placebo
43 Studies of Left Ventricular Dysfunction (SOLVD) Completed NCT00000516 Phase 3 enalapril
44 Surgical Treatment for Ischemic Heart Failure (STICH) Completed NCT00023595 Phase 3 Active Medication Alone
45 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
46 RIvoraxaban Safety and Efficacy in Patients With Mitral Stenosis Recruiting NCT03926156 Phase 3 Rivaroxaban;Warfarin
47 INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies Recruiting NCT02832544 Phase 3 Rivaroxaban (20 mg);Vitamin K antagonists (VKA)
48 Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation Recruiting NCT04171726 Phase 3 Edoxaban
49 Mandibular Advancement Device for Treatment of Obstructive Sleep Apnea and Its Impact on Cardiac Remodeling Recruiting NCT02948894 Phase 2, Phase 3
50 Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation. Active, not recruiting NCT01920698 Phase 3

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Genetic Tests for Heart Valve Disease

Anatomical Context for Heart Valve Disease

MalaCards organs/tissues related to Heart Valve Disease:

40
Heart, Testes, Kidney, Lung, Liver, Brain, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease

Publications for Heart Valve Disease

Articles related to Heart Valve Disease:

(show top 50) (show all 5820)
# Title Authors PMID Year
1
Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients? 42
32438839 2020
2
Preoperative Planning for Structural Heart Disease. 42
32471541 2020
3
Transcatheter Aortic Valve Replacement in the Coronavirus Disease 2019 (COVID-19) Era. 42
32452247 2020
4
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 54 61
20436747 2010
5
Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? 61 54
18307738 2008
6
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 54 61
17345160 2007
7
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]. 61 54
16029597 2005
8
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 61 54
16043943 2005
9
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. 61 54
15721858 2005
10
Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. 54 61
14973795 2004
11
Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. 61 54
14677016 2003
12
Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. 54 61
14674704 2003
13
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. 61 54
14608520 2003
14
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. 61 54
12761331 2003
15
Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. 54 61
12630582 2003
16
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. 54 61
12466135 2002
17
Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. 54 61
12270761 2002
18
Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. 54 61
9286500 1997
19
Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. 54 61
9104915 1997
20
Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis. 61 54
8467615 1993
21
Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. 61 54
8451600 1993
22
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 61 54
1611635 1992
23
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 61 54
1933972 1991
24
Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus. 54 61
1975008 1990
25
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. 61
31862249 2020
26
Atrial angiotensin-(1-12)/chymase expression data in patient of heart diseases. 61
32490094 2020
27
Implications of Renal Disease in Patients Undergoing Structural Interventions. 61
32471676 2020
28
Recent clinical trials in valvular heart diseases. 61
32398605 2020
29
ADAMTS19-associated heart valve defects: Novel genetic variants consolidating a recognizable cardiac phenotype. 61
32323311 2020
30
Desert hedgehog-primary cilia cross talk shapes mitral valve tissue by organizing smooth muscle actin. 61
32151560 2020
31
Quantification of Multiple Bacteria in Calcified Structural Valvular Heart Disease. 61
31605771 2020
32
Circulating extracellular vesicles from patients with valvular heart disease induce neutrophil chemotaxis via FOXO3a and the inhibiting role of dexmedetomidine. 61
32516026 2020
33
Molecular mechanisms involved in high glucose-induced valve calcification in a 3D valve model with human valvular cells. 61
32307869 2020
34
Cardiovascular Magnetic Resonance as a complementary method to Transthoracic Echocardiography for Aortic Valve Area Estimation in patients with Aortic Stenosis: A systematic review and meta-analysis. 61
32535246 2020
35
Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. 61
32371675 2020
36
Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults. 61
32248556 2020
37
Cardiac hypertrophic risk markers of left ventricle and left atrium in chronic heart failure due to aortic and mitral valve disease. 61
32571097 2020
38
Peguero-Lo Presti criteria for diagnosis of left ventricular hypertrophy: a cardiac magnetic resonance validation study. 61
32251077 2020
39
Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling. 61
32503311 2020
40
Prognostic role of moderate functional tricuspid regurgitation in length of hospitalization in patients undergoing isolated coronary artery bypass grafting. 61
32200479 2020
41
Tele-rehabilitation and hospital-based cardiac rehabilitation are comparable in increasing patient activation and health literacy: A pilot study. 61
31702397 2020
42
Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition. 61
32175673 2020
43
Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. 61
32524327 2020
44
A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies. 61
32558678 2020
45
A novel variant in MAP3K7 associated with an expanded cardiospondylocarpofacial syndrome phenotype. 61
32299812 2020
46
The role of stress concentration in calcified bicuspid aortic valve. 61
32517630 2020
47
Sinus Rhythm Conduction Properties across Bachmann's Bundle: Impact of Underlying Heart Disease and Atrial Fibrillation. 61
32560096 2020
48
Implications of Atrial Fibrillation Among Patients With Atherosclerotic Cardiovascular Disease Undergoing Noncardiac Surgery. 61
32331712 2020
49
Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. 61
32574395 2020
50
Clinical factors associated with baseline history of atrial fibrillation and subsequent clinical outcomes following initial implantable cardioverter-defibrillator placement. 61
32297348 2020

Variations for Heart Valve Disease

ClinVar genetic disease variations for Heart Valve Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SMC1A NM_001281463.1(SMC1A):c.730_732AAG[2] (p.Lys246del)short repeat Pathogenic 180197 rs727503773 X:53439900-53439902 X:53412950-53412952

Expression for Heart Valve Disease

Search GEO for disease gene expression data for Heart Valve Disease.

Pathways for Heart Valve Disease

Pathways related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.94 NPPB IL1R1 IL1B HTR2B HTR2A
2
Show member pathways
11.66 TGFB1 NPPB NPPA CTF1
3 11.55 TGFB1 IL1R1 IL1B
4 11.51 MIR423 MIR29B1 MIR21 MIR205 MIR126
5
Show member pathways
11.46 TGFB1 IL1R1 IL1B
6 10.34 TGFB1 IL1B

GO Terms for Heart Valve Disease

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TGFB1 NPPB NPPA IL1R1 IL1B CTF1
2 extracellular space GO:0005615 9.36 TGFB1 NPPB NPPA MIR423 MIR29B1 MIR21

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.96 TGFB1 IL1R1 IL1B CTF1
2 positive regulation of cell migration GO:0030335 9.93 TGFB1 MIR29B1 MIR21 IL1B
3 positive regulation of cell proliferation GO:0008284 9.93 TGFB1 MIR21 IL1B HTR2B HTR2A CTF1
4 cellular calcium ion homeostasis GO:0006874 9.83 TGFB1 HTR2B HTR2A
5 positive regulation of inflammatory response GO:0050729 9.82 MIR21 MIR126 IL1B
6 cellular response to mechanical stimulus GO:0071260 9.79 TGFB1 NPPA IL1B
7 positive regulation of MAP kinase activity GO:0043406 9.76 TGFB1 HTR2B HTR2A
8 positive regulation of fat cell differentiation GO:0045600 9.75 MIR29B1 MIR21 HTR2A
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.74 TGFB1 MIR499A MIR126
10 negative regulation of angiogenesis GO:0016525 9.73 NPPB MIR21 CNMD APOH
11 positive regulation of cell division GO:0051781 9.71 TGFB1 IL1B HTR2B
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 TGFB1 MIR21 IL1B
13 miRNA mediated inhibition of translation GO:0035278 9.67 MIR499A MIR29B1 MIR21 MIR205
14 behavior GO:0007610 9.65 HTR2B HTR2A
15 negative regulation of systemic arterial blood pressure GO:0003085 9.65 NPPB NPPA
16 negative regulation of endothelial cell proliferation GO:0001937 9.65 MIR21 CNMD APOH
17 positive regulation of cardiac muscle cell differentiation GO:2000727 9.64 TGFB1 MIR499A
18 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.63 MIR29B1 MIR21
19 cGMP biosynthetic process GO:0006182 9.62 NPPB NPPA
20 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPB NPPA
21 regulation of calcium ion transmembrane transport via high voltage-gated calcium channel GO:1902514 9.61 NPPA MIR21
22 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.6 MIR21 APOH
23 serotonin receptor signaling pathway GO:0007210 9.59 HTR2B HTR2A
24 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.56 IL1R1 IL1B
25 regulation of blood vessel remodeling GO:0060312 9.55 TGFB1 MIR29B1
26 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 TGFB1 MIR21 MIR126 HTR2B HTR2A
27 positive regulation of potassium ion export across plasma membrane GO:1903766 9.51 NPPA MIR21
28 positive regulation of vascular endothelial cell proliferation GO:1905564 9.5 MIR499A MIR21 MIR126
29 gene silencing by miRNA GO:0035195 9.5 MIR499A MIR423 MIR3909 MIR29B1 MIR21 MIR205
30 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.49 HTR2B HTR2A
31 cGMP-mediated signaling GO:0019934 9.43 NPPB NPPA HTR2B
32 regulation of aorta morphogenesis GO:1903847 9.4 MIR29B1 MIR205
33 positive regulation of metalloendopeptidase activity GO:1904685 8.8 MIR29B1 MIR21 MIR205

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR499A MIR423 MIR3909 MIR29B1 MIR21 MIR205
2 serotonin binding GO:0051378 9.16 HTR2B HTR2A
3 hormone receptor binding GO:0051427 8.96 NPPB NPPA

Sources for Heart Valve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....